Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – Equities researchers at Leerink Swann lowered their FY2019 EPS estimates for Jazz Pharmaceuticals in a report issued on Monday, October 15th. Leerink Swann analyst A. Fadia now anticipates that the specialty pharmaceutical company will post earnings per share of $13.63 for the year, down from their prior estimate of $13.83. Leerink Swann has a “Outperform” rating and a $210.00 price target on the stock. Leerink Swann also issued estimates for Jazz Pharmaceuticals’ FY2020 earnings at $17.98 EPS, FY2021 earnings at $20.87 EPS and FY2022 earnings at $23.15 EPS.
JAZZ has been the subject of several other reports. BidaskClub downgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, September 12th. Evercore ISI reissued a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Friday, July 13th. Stifel Nicolaus boosted their target price on shares of Jazz Pharmaceuticals from $180.00 to $205.00 and gave the stock a “buy” rating in a research report on Wednesday, August 8th. Cantor Fitzgerald set a $203.00 target price on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 7th. Finally, B. Riley boosted their target price on shares of Jazz Pharmaceuticals from $211.00 to $219.00 and gave the stock a “buy” rating in a research report on Tuesday, June 26th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $193.32.
JAZZ stock opened at $156.00 on Wednesday. The company has a quick ratio of 3.62, a current ratio of 3.76 and a debt-to-equity ratio of 0.54. The company has a market capitalization of $10.16 billion, a price-to-earnings ratio of 16.32, a price-to-earnings-growth ratio of 0.92 and a beta of 1.04. Jazz Pharmaceuticals has a 12 month low of $128.58 and a 12 month high of $184.00.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $3.49 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.23 by $0.26. The company had revenue of $500.48 million during the quarter, compared to the consensus estimate of $469.85 million. Jazz Pharmaceuticals had a net margin of 24.20% and a return on equity of 25.47%.
In related news, CEO Bruce C. Cozadd sold 1,600 shares of the company’s stock in a transaction on Wednesday, August 1st. The shares were sold at an average price of $173.90, for a total transaction of $278,240.00. Following the completion of the sale, the chief executive officer now directly owns 282,515 shares of the company’s stock, valued at approximately $49,129,358.50. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Rick E. Winningham sold 16,639 shares of the company’s stock in a transaction on Friday, August 10th. The stock was sold at an average price of $176.18, for a total transaction of $2,931,459.02. Following the sale, the director now directly owns 15,594 shares of the company’s stock, valued at $2,747,350.92. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 34,978 shares of company stock valued at $6,030,128. 3.90% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Oakbrook Investments LLC bought a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter worth $303,000. Aperio Group LLC raised its stake in Jazz Pharmaceuticals by 5.3% during the 3rd quarter. Aperio Group LLC now owns 11,656 shares of the specialty pharmaceutical company’s stock valued at $1,960,000 after purchasing an additional 587 shares during the last quarter. Nisa Investment Advisors LLC raised its stake in Jazz Pharmaceuticals by 345.3% during the 3rd quarter. Nisa Investment Advisors LLC now owns 23,155 shares of the specialty pharmaceutical company’s stock valued at $3,893,000 after purchasing an additional 17,955 shares during the last quarter. Andra AP fonden raised its stake in Jazz Pharmaceuticals by 1.4% during the 3rd quarter. Andra AP fonden now owns 37,200 shares of the specialty pharmaceutical company’s stock valued at $6,254,000 after purchasing an additional 500 shares during the last quarter. Finally, PGGM Investments acquired a new position in Jazz Pharmaceuticals during the 3rd quarter valued at $8,593,000. 92.52% of the stock is owned by institutional investors and hedge funds.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
See Also: Understanding each part of a balance sheet
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.